1.00
+0.0037(+0.37%)
Currency In USD
| Previous Close | 1 |
| Open | 0.98 |
| Day High | 1.01 |
| Day Low | 0.96 |
| 52-Week High | 3.92 |
| 52-Week Low | 0.86 |
| Volume | 117,814 |
| Average Volume | 228,213 |
| Market Cap | 60.57M |
| PE | -0.58 |
| EPS | -1.71 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 2.02 |
| Change | 0 |
If you invested $1000 in Acumen Pharmaceuticals, Inc. (ABOS) since IPO date, it would be worth $49.75 as of May 09, 2025 at a share price of $1. Whereas If you bought $1000 worth of Acumen Pharmaceuticals, Inc. (ABOS) shares 3 years ago, it would be worth $302.11 as of May 09, 2025 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
GlobeNewswire Inc.
May 07, 2025 8:00 PM GMT
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire Inc.
May 06, 2025 8:00 PM GMT
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire Inc.
Apr 02, 2025 11:00 AM GMT
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's DiseaseNEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceutical